Guselkumab vs. Golimumab for Psoriatic Arthritis
This study is comparing two medications, guselkumab and golimumab, for people with psoriatic arthritis (PsA) whose current treatment (a TNF inhibitor) isn't working well enough. Researchers want to see if switching to guselkumab, which works in a different way, is more effective than switching to another TNF inhibitor like golimumab. You could be eligible if you are between 18 and 80 years old, have active PsA, and have not responded well to a TNF inhibitor. The study will measure success by looking at how many participants achieve low disease activity and clear or almost clear psoriasis after 12 months. The current status of this study is unclear.
- Study design
- This is an open-label, randomized study involving 63 participants. It compares two different drug treatments for psoriatic arthritis.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main study outcomes are measured at 12 months, indicating participants will be followed for at least this long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
At a glance
Conditions
Where it's being run
14 sites across 10 statesStudy leadership
- Alexis Ogdie-Beatty, MD, MSCE · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Achievement of cDAPSA low disease activity12 Months
Clinical Disease Activity in Psoriatic Arthritis (cDAPSA): a combination score of tender joint count, swollen joint count, patient assessment of pain, and patient global assessment of disease activity. Scale from 0-154 where higher figures indicate worse status. Remission is considered ≤4 and low disease activity \>4 to ≤13.
- Investigator Global Assessment of Psoriasis of Clear or Almost Clear12 Months
Investigator global assessment (IGA) of psoriasis. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).